Physician profile
Jose M Garcia Mateo
NPI 1932275484
$944,576.12
in general payments reported to CMS, 2019-2025
34 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176K · 2020: $80K · 2021: $127K · 2022: $138K · 2023: $128K · 2024: $121K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $324K · Travel and Lodging: $54K · Food and Beverage: $24K · Honoraria: $13K · Consulting Fee: $9,962 · Education: $40.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $324,249.70 |
| Travel and Lodging | $53,730.46 |
| Food and Beverage | $23,723.32 |
| Honoraria | $12,615.00 |
| Consulting Fee | $9,962.22 |
| Education | $40.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $256,839.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $164,349.80 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113,872.69 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $101,350.33 | 2021-2025 | |
| Amgen INC. | $92,607.82 | 2019-2025 | Repatha, Repatha, Tepezza |
| Sanofi-Aventis U.S. LLC | $66,005.15 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $49,927.15 | 2019-2024 | Xarelto, Invokana |
| Madrigal Pharmaceuticals | $42,024.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Corcept Therapeutics | $27,461.21 | 2021-2025 | Korlym |
| Eli Lilly Export S.A. Puerto Rico Branch | $18,243.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Medicure Pharma INC. | $4,500.00 | 2019 | |
| Abbvie INC. | $2,992.71 | 2019-2024 | |
| Abbott Laboratories | $667.25 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $476.82 | 2023-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $426.37 | 2021-2025 | Corevalve Evolut R |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $418.01 | 2019-2021 | |
| Bayer Puerto Rico INC. | $363.16 | 2023-2025 | Kerendia |
| Ascendis Pharma Endocrinology INC | $277.52 | 2025 | Skytrofa, Yorvipath |
| Radius Health, INC. | $230.24 | 2019-2025 | Tymlos |
| Pbg Puerto Rico LLC | $172.49 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $156.12 | 2022-2025 | |
| Edwards Lifesciences Corporation | $150.06 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $147.74 | 2019-2023 | Lifevest |
| Vifor Pharma, INC. | $136.50 | 2025 | Veltassa |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Perspectum Diagnostics Ltd | $117.00 | 2025 | |
| Dexcom, INC. | $112.30 | 2022-2024 | Dexcom G7 Gss (161) |
| Kyowa Kirin, INC. | $98.58 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $81.01 | 2022 | |
| Pfizer INC. | $72.68 | 2025 | |
| Boston Scientific Corporation | $68.78 | 2023 | Watchman |
| Glaxosmithkline, LLC. | $51.30 | 2025 | |
| Ionis Pharmaceuticals, INC. | $32.59 | 2025 | Tryngolza |
| Pfizer Pharmaceuticals LLC | $20.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Garcia Mateo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.